Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.

Cancer cell - 16 Nov 2010

Chen Edwin, Beer Philip A, Godfrey Anna L, Ortmann Christina A, Li Juan, Costa-Pereira Ana P, Ingle Catherine E, Dermitzakis Emmanouil T, Campbell Peter J, Green Anthony R

Abstract excerpt

The JAK2V617F mutation is associated with distinct myeloproliferative neoplasms, including polycythemia vera (PV) and essential thrombocythemia (ET), but it remains unclear how it generates disparate disorders. By comparing clonally-derived mutant and wild-type cells from individual patients, we demonstrate that the transcriptional consequences of JAK2V617F are subtle, and that JAK2V617F-heterozygous erythroid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Culture Techniques
Share to Interferons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Megakaryocytes

Share to Myeloproliferative Disorders

Share to Polycythemia Vera

Share to STAT1 Transcription Factor

Share to STAT5 Transcription Factor

Share to Thrombocythemia, Essential

Source

Open in PubMed Open full text

Identifiers

PMID: 21074499
DOI: 10.1016/j.ccr.2010.10.013
PMCID: PMC2996868

Genes

STAT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.PMID 21074499Read ↗

Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative DisordersSemantic proximity Read ↗

Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.Semantic proximity Read ↗

JAK-2 mutations and their relevance to myeloproliferative diseaseSemantic proximity Read ↗

A role for JAK2 mutations in myeloproliferative diseases.Semantic proximity Read ↗

JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.Semantic proximity Read ↗

Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Molecular analysis of phenotypic heterogeneity in JAK2V617F-positive myeloproliferative neoplasms reveals a potential target for therapy.Semantic proximity Read ↗

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.Semantic proximity Read ↗

Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms.Semantic proximity Read ↗

Impact of isolated germline JAK2V617I mutation on human hematopoiesisSemantic proximity Read ↗

Distinct effects of V617F and exon12-mutated JAK2 expressions on erythropoiesis in a human induced pluripotent stem cell (iPSC)-based model.Semantic proximity Read ↗

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera–like diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.